2022 is starting on a worrisome note; patience warranted
13/01/22 -"While the fundamental metrics (i.e. DCF and NAV) continue to point to healthy upside potential (taking into consideration the long-term virtues of Philips’ offerings), the near-term is fraught with ..."
Pages
63
Language
English
Published on
13/01/22
You may also be interested by these reports :
03/06/26
Despite a reduction in our target price, as discussed in the EPS section, our positive recommendation on Qiagen remains unchanged. This optimism is ...
29/05/26
Elekta’s Q4 results revealed an adjusted EBIT exceeding expectations, although sales fell short. The company offered qualitative guidance for ...
26/05/26
Piling up assets is no strategy
25/05/26
The modest TP reduction reflects downward revisions to DCF and NAV, driven by lower near-term earnings (as discussed in the ‘EPS’ section). While our ...